Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) CFO Benjamin Halladay sold 10,773 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $3.15, for a total value of $33,934.95. Following the sale, the chief financial officer directly owned 702,829 shares of the company’s stock, valued at $2,213,911.35. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Esperion Therapeutics Price Performance
Shares of ESPR stock opened at $3.15 on Friday. Esperion Therapeutics, Inc. has a 1-year low of $0.95 and a 1-year high of $4.18. The firm has a market cap of $811.72 million, a PE ratio of -52.50 and a beta of 1.07. The company has a 50-day moving average of $2.76 and a two-hundred day moving average of $3.11.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). The company had revenue of $80.10 million during the quarter, compared to analysts’ expectations of $84.52 million. Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on ESPR
Hedge Funds Weigh In On Esperion Therapeutics
Institutional investors have recently modified their holdings of the business. R Squared Ltd increased its position in shares of Esperion Therapeutics by 23.5% during the fourth quarter. R Squared Ltd now owns 15,173 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 2,890 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Esperion Therapeutics by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 38,955 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,614 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Esperion Therapeutics by 49.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 3,822 shares in the last quarter. Eaton Financial Holdings Company LLC increased its holdings in Esperion Therapeutics by 9.4% during the 4th quarter. Eaton Financial Holdings Company LLC now owns 46,595 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 4,000 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Esperion Therapeutics by 18.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,338 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 4,422 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
Featured Articles
- Five stocks we like better than Esperion Therapeutics
- How to Invest in the Biggest European Defense Surge in Decades
- The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
